Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Part of paid clinical trials in Tuscumbia, Alabama.
- Sponsor
- Novo Nordisk A/S
- Study ID
- NCT02863328
- Phase
- PHASE3
- Status
- Completed
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- semaglutide — DRUGOral administration once-daily.
- empagliflozin — DRUGOral administration once-daily.
Study Details
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
Key Dates
- Start date
- Aug 10, 2016
- Status verified
- Jul 2022
- Primary completion
- Aug 1, 2017
- Completion
- Mar 8, 2018
Study Design
- Enrollment
- 822 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 14 mg oral semaglutide
- Active Comparator: 25 mg empagliflozin
Primary Outcome Measure
Change in HbA1c [ Time Frame: Week 0, week 26 ]
Locations (48)
Find similar trials in Tuscumbia, AL
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Urinary Vitamin C Loss in Diabetic SubjectsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Personalized Environment and Genes StudyRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
- Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora PopulationsEnrolling By Invitation · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland